Regeneron Pharmaceuticals and Sanofi are spending $67.5 million to buy a special voucher held by BioMarin Pharmaceuticals in a bid to hasten regulatory review of their new cholesterol drug.
from WSJ.com: US Business http://ift.tt/1zxrNJ0
via IFTTT
from WSJ.com: US Business http://ift.tt/1zxrNJ0
via IFTTT
No comments:
Post a Comment